Skip to main content

NexImmune, Inc. (NEXI)

NASDAQ: NEXI · IEX Real-Time Price · USD
12.88 0.00 (0.00%)
Oct 22, 2021 4:00 PM EDT - Market closed
Market Cap293.03M
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out22.61M
EPS (ttm)-4.17
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume60,689
Open12.98
Previous Close12.88
Day's Range12.19 - 13.20
52-Week Range10.10 - 28.00
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 8, 2021

About NEXI

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; and NEXI-002, an autologous cell therapy, ...

IndustryBiotechnology
IPO DateFeb 12, 2021
Employees44
Stock ExchangeNASDAQ
Ticker SymbolNEXI
Full Company Profile

Financial Performance

Financial Statements

News

NexImmune to Present at the 2021 Cantor Virtual Global Healthcare Conference

GAITHERSBURG, Md., Sept. 27, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a target...

3 weeks ago - GlobeNewsWire

NexImmune to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

GAITHERSBURG, Md., Sept. 10, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a target...

1 month ago - GlobeNewsWire

NexImmune Reports Second Quarter 2021 Financial Results and Provides Business Updates

GAITHERSBURG, Md., Aug. 09, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targete...

2 months ago - GlobeNewsWire

NexImmune to Explore the Use of AIM™ Direct Injection Technology in Type 1 Diabetes

GAITHERSBURG, Md., Aug. 09, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targete...

2 months ago - GlobeNewsWire

NexImmune to Announce Second Quarter 2021 Financial Results and Provide Corporate Update on August 9, 2021

GAITHERSBURG, Md., July 27, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targete...

2 months ago - GlobeNewsWire

NexImmune Strengthens Management Team with Key Appointments

GAITHERSBURG, Md., July 14, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targete...

3 months ago - GlobeNewsWire

NexImmune to Present at the Raymond James 2021 Human Health Innovation Conference

GAITHERSBURG, Md., June 16, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targete...

4 months ago - GlobeNewsWire

NexImmune Announces Formation of Scientific Advisory Board

GAITHERSBURG, Md., May 27, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted...

4 months ago - GlobeNewsWire

NexImmune Announces Presentation of Preliminary Phase 1/2 Clinical Data at the 2021 American Society of Clinical Onco...

GAITHERSBURG, Md., May 19, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted...

5 months ago - GlobeNewsWire

NexImmune Reports First Quarter 2021 Financial Results and Recent Updates

GAITHERSBURG, Md., May 17, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted...

5 months ago - GlobeNewsWire

NexImmune Appoints Chad Rubin as Senior Vice President, Corporate Affairs

GAITHERSBURG, Md., April 21, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a target...

6 months ago - GlobeNewsWire

NexImmune Reports Fiscal Year 2020 Financial Results and Recent Updates

GAITHERSBURG, Md., March 31, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a target...

6 months ago - GlobeNewsWire

5 Recent Red-Hot IPOs Are Being Added to the Russell 2000 Next Week

Last year was a monster year for the initial public offering market, and 2021 looks like it could provide a repeat performance.

Other symbols:BOLTMASSMDWTOCDX
7 months ago - 24/7 Wall Street

NexImmune to Present at the 2021 Barclays Global Healthcare Conference

GAITHERSBURG, Md., March 02, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a target...

7 months ago - GlobeNewsWire

The Past Week's Notable Insider Buys: More Biotech IPOs, Bumble, Fiserv And More

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Biotech stocks and secondary and initial public offerings were well represented this week.

8 months ago - Benzinga

NexImmune Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase ...

GAITHERSBURG, Md., Feb. 17, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body's own...

8 months ago - GlobeNewsWire

NexImmune Announces Pricing of Upsized Initial Public Offering Nasdaq:NEXI

NexImmune, Inc., a clinical-stage biotechnology company developing a novel approach to immunotherapy...

8 months ago - GlobeNewswire

Immunotherapy biotech NexImmune files for an $86 million IPO

NexImmune, a Phase 1/2 biotech developing T cell immunotherapies for cancer, filed on Tuesday with the SEC to raise up to $86 million in an initial public offering.

9 months ago - NASDAQ

NexImmune IPO Registration Document (S-1)

NexImmune, Inc. has filed to go public with an IPO on the NASDAQ.

9 months ago - SEC